Welcome to BioSeeker Group!

Triple Analysis: Lung Cancer, Pancreatic Cancer and Peptides

Additional Information

Published Date Jan 7, 2013
Special Offer

You can deduct the full value of this report within 30 days of purchase towards a Cancer Highlights subscription.
Read more about becoming a Cancer Highlights subscriber here.

Pages 3439
PDF Fact Sheet View Fact Sheet for the report Triple Analysis: Lung Cancer, Pancreatic Cancer and Peptides in PDF
Format PDF
Publisher BioSeeker Group
Product Line

Find the Triple Analysis Report in oncology which best suits your needs by selecting any three (3) out of these 14 high impact Cancer Focus Areas.

Availability: In stock

$3,450.00

Quick Overview

This triple analysis focuses on cancer drug development strategies in both Lung Cancer and Pancreatic Cancer and by the compound strategy of Peptides.

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Lung Cancer, Pancreatic Cancer and Peptides.

    To find out more about Triple Analysis: Lung Cancer, Pancreatic Cancer and Peptides, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Lung Cancer, Pancreatic Cancer and Peptides is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

This triple analysis focuses on cancer drug development strategies in both Lung Cancer and Pancreatic Cancer and by the compound strategy of Peptides. Each of these three individual parts is evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different areas.

Below is a short synopsis of each part included in this report:

Part I: Lung Cancer
The lung cancer report part comprises defined and up to date development strategies for 416 lung cancer drugs within the portfolio of 218 investigators, from Ceased to Marketed. This part extensively analyses their 241 identified drug targets, organized into 237 drug target strategies, and assesses them in eight different compound strategies and and three subindications of lung cancer.
This part is based on the following publication:
Lung Cancer: A Decision Support Tool for Optimizing the Pipeline from Research To Market

Part II: Pancreatic Cancer
The pancreatic cancer report part comprises defined and up to date development strategies for 247 pancreatic cancer drugs within the portfolio of 158 investigators, from Ceased to Marketed. This part extensively analyses their 197 identified drug targets, organized into 163 drug target strategies, and assesses them in eight different compound strategies.
This part is based on the following publication:
Commercializing Pancreatic Cancer Drugs: The Faster Route to Consider Your Options and Position of Others

Part III: Peptides
The peptide drug report part comprises defined and up to date development strategies for 171 drugs in oncology within the portfolio of 114 companies world-wide, from Ceased to Marketed. The report extensively analyses their 132 identified drug targets, organized into 109 drug target strategies, and assesses them in 62 cancer indications.
This part is based on the following publication:
Cancer Peptides: From First-in-Class to Best-in-Class?

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies’ pipeline and portfolio planning (PPP) in cancer by:

* Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives

* Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug’s properties

* Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities

* Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities

* Supporting development of integrative molecule, pathway and disease area strategies

* Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for cancer drugs to insure that the optimal market conditions exist by the time the products are commercialized.

Key Topics Covered:

Part I: Lung Cancer
5.1 The Scope of this Report 31
6 Consider the Therapeutic Target Among Lung Cancer Drugs for the Highest Therapeutic Outcome and Return on Investment (241 Drug Targets) 35-526
7 Emerging New Products to Established Ones: Drug Target Strategies of Lung Cancer Drugs by their Highest Stage of Development (237 Drug Target Strategies and 416 Lung Cancer Drugs) 527-817
8 Compound Strategies at Work: Competitive Benchmarking of Lung Cancer Drugs by Compound Strategy (8 Compound Strategies) 818-870
9 Selecting Subindication for Lung Cancer Drugs (Three Subindications of Lung Cancer) 871-898
10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Lung Cancer Drug Pipeline by Investigator (218 Companies) 899-1299
11 Disclaimer 1300
12 Drug Index 1301
13 Company Index 1314
Figures: Includes 7 Figures
Tables: Includes 284 Tables
Total Number of Pages: 1323

Part II: Pancreatic Cancer
5.1 The Scope of this Report 27
6 Consider the Therapeutic Target Among Pancreatic Cancer Drugs for the Highest Therapeutic Outcome and Return on Investment (197 Drug Targets) 31-422
7 Emerging New Products to Established Ones: Drug Target Strategies of Pancreatic Cancer Drugs by their Highest Stage of Development (163 Drug Target Strategies and 247 Drugs) 423-612
8 Compound Strategies at Work: Competitive Benchmarking of Pancreatic Cancer Drugs by Compound Strategy (8 Compound Strategies) 613-651
9 Pipeline and Portfolio Planning: Competitive Benchmarking of the Pancreatic Cancer Drug Pipeline by Investigator (158 Investigators and 247 Drugs) 652-1088
10 Drug Index 1091
11 Company Index 1098
Figures: Includes 7 Figures
Tables: Includes 218 Tables
Total Number of Pages: 1,103

Part III: Peptides
5.1 The Scope of this Report 27
6 Consider the Therapeutic Target Among Peptide Drugs in Cancer for the Highest Therapeutic Outcome and Return on Investment (132 Drug Targets) 31-252
7 First-in-Class and Me-too Analysis of Peptide Drugs in Cancer (109 Drug Target Strategies and 171 Drugs) 253-267
8 Is First-in-Class the Best-in-Class? (109 Drug Target Strategies and 171 Drugs) 268-387
9 The Competition through Close Mechanistic Approximation of Peptide Drugs in Cancer 388
10 Selecting Indication for Peptide Drugs in Oncology ( 62 Cancer Indications) 391-475
11 Pipeline and Portfolio Planning: Competitive Benchmarking of the Cancer Peptide Drug Pipeline by Investigator (114 Investigators and 171 Drugs) 476-1001
12 Disclaimer 1002
Figures: Includes 5 Figures
Tables: Includes 232 Tables
Total Number of Pages: 1,013

This Report Includes the Following Companies:
7TM Pharma
A&G Pharmaceutical
AB Science
Abbott
Acceleron Pharma
Active Biotech
Adherex
Advanomics
Advantagene
Advaxis
AEgera
AEterna Zentaris
Affymax
Agennix
Agenus
Aida Pharmaceuticals
Aileron Therapeutics
Alchemia
Alder Biopharmaceuticals
Alethia Biotherapeutics
Allos Therapeutics
Allostera
Allosterix
AlphaVax
Altor BioScience
Ambrilia Biopharma
Amgen
Anchor Therapeutics
AngioChem
Angstrom Pharmaceuticals
Antisense Pharma
Antisoma
Anza Therapeutics
AplaGen Biopharmaceuticals
Apogee Biotechnology
ApopLogic Pharmaceuticals
Apotex
Ardana
Ardea Biosciences
Ariad
ArQule
Array BioPharma
Ascenta Therapeutics
Astellas
AstraZeneca
Attenuon
AVEO
AVI BioPharma
Avila Therapeutics
Axelar
Baxter International
Bayer
Benitec
Betapharma
Biogen Idec
Biokine Therapeutics
BioLineRx
Bionovo
BioNumerik
BioSante
Boehringer Ingelheim
Bristol-Myers Squibb
BTG
Calando Pharmaceuticals
Camurus
CanBas
Cancer Advances
Cancer Innovations
Cancer Research Technology
CDG Therapeutics
Celator Pharmaceuticals
Celecure
Celera
Celgene
Cell Therapeutics
Celldex Therapeutics
Celsion
Celtic Pharma
Center of Molecular Immunology
Cephalon
CG Therapeutics
Chemokine Therapeutics
Chiasma
Chong Kun Dang
Circadian Technologies
Clavis Pharma
Cleveland BioLabs
Clinuvel
CLL Pharma
CompleGen
Compugen
Cornerstone Pharmaceuticals
Coronado Biosciences
Critical Outcome Technologies
CritiTech
Curaxis
Curis
Cyclacel
Cylene Pharmaceuticals
Cynvec
CytImmune Sciences
Cytokinetics
CytRx
Daiichi Sankyo
Dainippon Sumitomo Pharma
Dara Biosciences
Debiopharm
Dendreon
Digna Biotech
Dong-A
Dongkook Pharm
ECI
EGEN Inc
Eisai
Elara Pharmaceuticals
Eli Lilly
Endo Pharmaceuticals
Endocyte
Enkam Pharmaceuticals
EntreMed
Epeius Biotechnologies
EpiCept
Esperance Pharmaceuticals
Exelixis
FibroGen
Formula Pharmaceuticals
Fresenius
Galapagos
Galectin Therapeutics
Galena Biopharma
Gemin X Biotechnologies
Generex
Genmab
GENova Biotherapeutics
Genovax
Genta
GenVec
Genzyme
Geron
Gilead Sciences
GlaxoSmithKline
Glide Pharma
Gliknik
GlobeImmune
GlycoGenesys
GP Pharm
Gradalis
Gryphon Therapeutics
Hanmi
Hoffmann-La Roche
Human Genome Sciences
Idera Pharmaceuticals
ImmunoCellular Therapeutics
Immunocore
ImmunoGen
Immunomedics
Immunotope
ImmuPharma
Immutep
Incyte Corporation
Infinity Pharmaceuticals
Innate Pharma
Innovive
Inovio
Insmed
Insys Therapeutics
Intezyne Technologies
Introgen Therapeutics
Ipsen
ISA Pharmaceuticals
Isis Pharmaceuticals
Jennerex Biotherapeutics
Johnson & Johnson
Kadmon
KAEL-GemVax
Karyon-CTT
Kiadis
Kirax
Kyowa Hakko Kirin
Lee’s Pharmaceutical
Leo
Ligand
Lorus Therapeutics
MacroGenics
Marillion Pharmaceuticals
MBiotec
Meda
MediGene
Mediolanum
Medisyn Technologies
Menarini
Merck & Co
Merck KGaA
Merrimack
Mersana Therapeutics
MethylGene
Micromet
Mirna Therapeutics
MolMed
Mologen
Mycenax
Nektar Therapeutics
Nemod Biotherapeutics
Nereus Pharmaceuticals
Nerviano Medical Sciences
Neurobiological Technologies
Neurocrine Biosciences
NewSouth Innovations
Nidus Laboratories
Nippon Kayaku
Nippon Shinyaku
Non-industrial source
Novacea
NovaLead
Novartis
Novogen
NPS Pharmaceuticals
Oasmia
OncoGenex Pharmaceuticals
OncoMed
OncoTherapy Science
Oncothyreon
Oncozyme Pharma
Orchestra Therapeutics
OSI Pharmaceuticals
Oxford BioMedica
OXiGENE
Paladin Labs
PanaGin
Patrys
PBL Therapeutics
Pepscan Therapeutics
Peptagen
PepTx
Pfizer
Pharmacyclics
PharmaGap
PharmaMar
Pharmexa
Philogen
Pierre Fabre
Piramal
Pro-Pharmaceuticals
Progen Pharmaceuticals
ProMetic Life Sciences
Protagonist
Protgen
Q Chip
QLT
Raptor Pharmaceutical
Ras Therapeutics
Reata Pharmaceuticals
Receptor BioLogix
Regeneron
Regulon
RESprotect
Rexahn
Rigel
Rottapharm Madaus
Samyang
Sanofi
Sanofi-Aventis
Santaris Pharma
Sarepta Therapeutics
Sareum
SciClone Pharmaceuticals
Seattle Genetics
Serometrix
ShimodaAtlantic Oncology
Shire
Sigma-Tau
Silence Therapeutics
Simcere Pharmaceuticals
Sirnaomics
Soligenix
Spectrum Pharmaceuticals
SRI International
SuperGen
Supratek Pharma
Switch Pharma
Symphogen
SynDevRx
Synta Pharmaceuticals
Tactic Pharma
Taiho
Takeda
Talon Therapeutics
Tapestry Pharmaceuticals
Tau Therapeutics
Taxolog
Tekmira Pharmaceuticals
Telik
Teva
Thallion Pharmaceuticals
Therion Biologics
Theryte
Titan Pharmaceuticals
TopoTarget
Tracon Pharmaceuticals
Tragara Pharmaceuticals
Transgene
TriAct Therapeutics
Trion Pharma
UCB
UMN Pharma
Unigene
United Biomedical
Valeant
Vaxil BioTherapeutics
Vaxon Biotech
VaxOnco
Vernalis
Vertex Pharmaceuticals
Vical
Wilex
Vion Pharmaceuticals
VioQuest
VioQuest Pharmaceuticals
ViroMed
Wyeth
Xerion
Xigen
Xoma
Yakult Honsha
YM BioSciences
Zelos Therapeutics
Zensun
Zeria
Zhejiang Beta Pharma
Zivena
A Shortlist of Drugs Included are:
A6
abarelix
ABT-510
AEG-35156
AEZS-108
afamelanotide
afatinib
aflibercept
AGS-1C4D4
amrubicin hydrochloride
angiopep+paclitaxel
apricoxib
ARC-100
ARQ-197
astuprotimut-r
bardoxolone methyl
belagenpumatucel-L
belotecan hydrochloride
bevacizumab
BIBF-1120
bosutinib
brivanib alaninate
brivudine
Cabozantinib
canfosfamide hydrochloride
capecitabine
catumaxomab
CBP-501
celecoxib
cetuximab
CG-201
cilengitide
cixutumumab
conatumumab
corticorelin acetate
CPI-613
crizotinib
CRLX-101
dacomitinib
dalotuzumab
dasatinib
deslorelin
docetaxel
doxorubicin
E-75
E-7820
emepepimut-S
endostatin
eniluracil
enzastaurin hydrochloride
EP-100
erlotinib
etoposide (1)
etoposide phosphate
everolimus
FPI-01
ganitumab
gefitinib
goserelin
GSK-1120212
GV-1001
GVAX
GX-301
Her-2/Neu peptides
histrelin
icotinib hydrochloride
imatinib mesilate
imMucin
IMP-321
iniparib
interferon (gamma1b)
ipilimumab
IPP-204106
irinotecan
irinotecan hydrochloride
ISA-P53-01
kahalalide F
KD032
L19-IL2
lanreotide
lapatinib ditosylate
lestaurtinib
leukemia vaccine
leuprolide
leuprolide acetate
leuprorelin
LipoVIL12
masitinib
MDX-1379
MetXia
MKC-1
mocetinostat
motesanib diphosphate
motexafin gadolinium
nadroparin
NAFB001
necitumumab
netupitant
nimotuzumab
oblimersen sodium
octreotide
octreotide, LAR
olaparib
OTS-102
ozarelix
P-276-00
paclitaxel
paclitaxel polyglumex
PancAtak
panobinostat
pasireotide
pasireotide LAR
pazopanib hydrochloride
PCI-27483
pemetrexed disodium
pentamidine isethionate
perifosine
plitidepsin
polyclonal antibody stimulator
PX-12
ramucirumab
Rexin-G
rindopepimut
romidepsin
romurtide
RX-0201
selumetinib
siltuximab
sorafenib tosylate
sotatercept
ß-lapachone
sunitinib malate
Survivac
talactoferrin alfa
talminogene laherparepvec
tegafur + uracil
temsirolimus
thymalfasin
tigatuzumab
TM-30339
tocilizumab
topotecan
trabedersen
trastuzumab
triciribine phosphate
TS-1
tucotuzumab celmoleukin
vapreotide, immediate-release
varlitinib
vismodegib
vitespen
volociximab
VX-001
WX-671
Z-360

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Lung Cancer, Pancreatic Cancer and Peptides.
    To find out more about Triple Analysis: Lung Cancer, Pancreatic Cancer and Peptides, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Lung Cancer, Pancreatic Cancer and Peptides is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Other selected research from the 'Triple Analysis' category:


Triple Analysis: Melanoma, Pancreatic Cancer and Apoptosis
This triple analysis focuses on cancer drug development strategies in both Melanoma and Pancreatic Cancer and by the mechanism/target/effect of Apoptosis. Learn More


Triple Analysis: Lymphoma, Melanoma and Peptides
This triple analysis focuses on cancer drug development strategies in both Lymphoma and Melanoma and by the compound strategy of Peptides. Learn More

Other selected research from the 'Oncology' category:


Triple Analysis: Melanoma, Prostate Cancer and Apoptosis
This triple analysis focuses on cancer drug development strategies in both Melanoma and Prostate Cancer and by the mechanism/target/effect of Apoptosis. Learn More


Triple Analysis: Lung Cancer, Prostate Cancer and Cancer Vaccines
This triple analysis focuses on cancer drug development strategies in both Lung Cancer and Prostate Cancer and by the mechanism/target/effect of Cancer Vaccines. Learn More